商务合作
动脉网APP
可切换为仅中文
AQNEURSA is approved in the U.S. and Europe for neurological manifestations of Niemann-Pick disease type C and in the U.S. as the first and only treatment for Ataxia in patients diagnosed with Ataxia-Telangiectasia
AQNEURSA 在美国和欧洲获批用于尼曼-匹克病 C 型的神经系统表现,并在美国作为首个且唯一用于治疗确诊为共济失调毛细血管扩张症患者的共济失调的药物。
Shionogi is committed to seamless continuity of care for patient communities in the U.S. and to achieving access in Europe
盐野义致力于确保美国患者群体的护理无缝衔接,并致力于实现欧洲市场的可及性。
OSAKA, Japan, November 18, 2026
日本大阪,2026年11月18日
– Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') announced that it has completed the acquisition of IntraBio Inc. (“IntraBio”). The acquisition adds AQNEURSA
– 盐野义制药株式会社(总部:日本大阪;首席执行官:手代木功博士;以下简称“盐野义”)宣布,已完成对 IntraBio Inc.(“IntraBio”)的收购。此次收购将 AQNEURSA
®
®
(levacetylleucine) and additional rare disease capabilities to Shionogi's growing global portfolio.
(左乙酰亮氨酸)以及额外的罕见病能力,纳入盐野义不断增长的全球产品组合。
AQNEURSA was approved by the U.S. Food and Drug Administration in 2024 and by the European Medicines Agency (EMA) in January 2026 for neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kg in the U.S. and 20 kg in Europe.¹
AQNEURSA 于2024年获得美国食品药品监督管理局批准,并于2026年1月获得欧洲药品管理局(EMA)批准,用于治疗成人及体重至少为15公斤(美国)或20公斤(欧洲)的儿科患者的尼曼-匹克病C型(NPC)神经系统表现。¹
,
,
² The FDA approved AQNEURSA as the first and only option for the treatment of Ataxia in adults and pediatric patients diagnosed with Ataxia-Telangiectasia (A-T) weighing at least 15 kg in September 2026.³
² 美国食品药品监督管理局(FDA)于2026年9月批准AQNEURSA作为首个且唯一用于治疗确诊为毛细血管扩张性共济失调症(A-T)且体重至少15公斤的成人和儿科患者共济失调的药物。³
AQNEURSA is currently under review by the EMA for adult and pediatric patients diagnosed with A-T and it is currently being studied for the treatment of CACNA1A disorders in a Phase III, randomized, placebo-controlled, double-blind, crossover study. Shionogi will continue programs initiated by IntraBio and explore additional opportunities to research AQNEURSA in additional rare disease conditions..
AQNEURSA 目前正由欧洲药品管理局(EMA)审评,用于确诊为共济失调毛细血管扩张症(A-T)的成人和儿科患者;同时,一项 III 期、随机、安慰剂对照、双盲、交叉设计的研究正在评估其治疗 CACNA1A 相关疾病的疗效。Shionogi 将继续推进由 IntraBio 启动的项目,并探索在其他罕见病领域开展 AQNEURSA 研究的更多机会。
“With the closing of the IntraBio acquisition, we welcome AQNEURSA to Shionogi’s growing portfolio and strengthen our global capabilities with additional rare disease expertise,” said Isao Teshirogi, Ph.D., CEO of Shionogi. “For nearly 150 years, Shionogi has grown our business by adapting to the changing needs of patients.
“随着IntraBio收购案的完成,我们欢迎AQNEURSA加入盐野义不断扩展的产品组合,并通过增添罕见病领域的专业知识来增强我们的全球能力。”盐野义首席执行官手代木功博士表示。“近150年来,盐野义通过适应患者不断变化的需求而实现了业务增长。
This milestone is the latest representation of our steadfast commitment to deliver innovative medicines to protect the health and wellbeing of the patients we serve.”.
这一里程碑最新体现了我们坚定不移的承诺,即提供创新药物,以保护我们所服务患者的健康与福祉。
Under the terms of the agreement announced on October 5, 2026, Shionogi Inc., a New Jersey-based subsidiary of Shionogi, paid a lump sum of USD 2.0 billion to acquire all outstanding shares of IntraBio, including global intellectual property and commercialization rights for AQNEURSA.
根据2026年10月5日宣布的协议条款,盐野义制药旗下位于新泽西州的子公司Shionogi Inc.支付了一笔20亿美元的 lump sum(一次性款项),以收购IntraBio的所有流通股,包括AQNEURSA的全球知识产权和商业化权利。
“Through acquisitions, integrations and strategic hires, Shionogi is building a strong, sustainable rare disease presence with a clear purpose: to make a meaningful difference for patients,” said Nathan McCutcheon, President and CEO, Shionogi Inc. “We have the infrastructure, portfolio, and commitment to deliver the medicines, patient support and services, and the scientific expertise and determination to advance new treatment options for tomorrow.”.
“通过收购、整合和战略性招聘,盐野义正在构建强大且可持续的罕见病业务布局,其目标明确:为患者带来切实的改变。”盐野义美国公司总裁兼首席执行官内森·麦卡琴表示,“我们拥有相应的基础设施、产品组合以及承诺,能够提供药物、患者支持与服务;同时具备科学专业知识和决心,推动未来新治疗方案的研发。”
”We look forward to partnering with patient groups representing people living with these devastating conditions, and learning from patients, families and carers about the challenges they face and how we can best help improve their lives,” said Huw Tippett, CEO, Shionogi Europe.
“我们期待与代表这些严重疾病患者的患者组织合作,并向患者、家属及照护者了解他们所面临的挑战,以及我们如何能最有效地帮助改善他们的生活,”盐野义欧洲公司首席执行官休·蒂佩特表示。
“We look forward to partnering with the Shionogi team. The recent U.S. regulatory approval of AQNEURSA, the first targeted treatment for A-T, has brought hope to many children and their families. With the additional reach and resources that Shionogi brings, we are hopeful that more A-T families will be able to access this treatment,” said Brad Margus, Founder, A-T Children’s Project..
“A-T儿童项目”创始人布拉德·马格斯表示:“我们期待与盐野义团队建立合作伙伴关系。近期,首个针对共济失调毛细血管扩张症(A-T)的靶向疗法AQNEURSA在美国获得监管批准,为许多患儿及其家庭带来了希望。借助盐野义所拓展的覆盖范围和资源,我们有信心让更多A-T患者家庭能够获得这一治疗。”
“For the Niemann-Pick community, this acquisition is an opportunity to build on progress to date for people living with NPC and their families. We are deeply grateful to IntraBio for securing approval for AQNEURSA and their support of our community. We look forward to working with Shionogi to expand access and ensure this important therapy reaches the families who need it most,” said Heather Teal, Executive Director, National Niemann-Pick Disease Foundation..
“对于尼曼-匹克病社群而言,此次收购是一个在迄今为尼曼-匹克病C型(NPC)患者及其家庭所取得的进展基础上继续推进的契机。我们深切感谢IntraBio公司成功获得AQNEURSA的批准以及他们对我们的社群的支持。我们期待与盐野义制药合作,扩大药物可及性,确保这一重要疗法能够惠及最需要的家庭。”美国国家尼曼-匹克病基金会执行董事希瑟·蒂尔表示。
Following
关注
the acquisition of RADICAVA ORS
RADICAVA ORS 的收购
®
注册商标符号
(edaravone) earlier this year
(依达拉奉)今年早些时候
, a treatment for amyotrophic lateral sclerosis (ALS), Shionogi has established a strong commercial and medical affairs foundation in rare disease, including expertise serving patients with neurodegenerative diseases. Bringing IntraBio to Shionogi expands that foundation with new capabilities to support the company’s growing rare disease pipeline, which includes clinical programs in Pompe disease, Fragile X syndrome and Jordan’s syndrome, as well as additional early-stage rare neurodegenerative disease programs..
作为肌萎缩侧索硬化症(ALS)的一种治疗药物,盐野义已在罕见病领域建立了强大的商业和医学事务基础,包括在服务神经退行性疾病患者方面的专业知识。将IntraBio纳入盐野义,通过新增能力进一步巩固了这一基础,以支持公司不断增长的罕见病产品管线,其中包括针对庞贝氏病、脆性X综合征和乔丹综合征的临床项目,以及更多早期的罕见神经退行性疾病项目。
About AQNEURSA
关于AQNEURSA
®
®
AQNEURSA
AQNEURSA
®
®
is approved in the U.S. for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kg, and for the treatment of ataxia in adult and pediatric patients diagnosed with Ataxia-Telangiectasia (A-T) weighing at least 15 kg.
已在美国获批,用于治疗体重至少15公斤的成人和儿科患者的尼曼-匹克病C型(NPC)的神经系统表现,以及用于治疗体重至少15公斤、诊断为毛细血管扩张性共济失调(A-T)的成人和儿科患者的共济失调。
In Europe, it has also been approved for the treatment of neurological manifestations of NPC in adults and pediatric patients aged 6 years and older weighing at least 20 kg in combination with miglustat, or as monotherapy in patients where miglustat is not tolerated. AQNEURSA is currently under review by the EMA for adults and pediatric patients diagnosed with Ataxia-Telangiectasia (A-T)..
在欧洲,该药也已获批用于成人及6岁及以上、体重至少20公斤的儿科患者,与米格司他联合治疗尼曼-匹克病C型(NPC)的神经系统表现,或作为单药疗法用于无法耐受米格司他的患者。目前,欧洲药品管理局(EMA)正在审评AQNEURSA用于确诊为共济失调毛细血管扩张症(A-T)的成人及儿科患者的适应症。
About Niemann-Pick Disease Type C
关于尼曼-匹克病C型
Niemann-Pick disease type C (NPC) is an ultra-rare, progressive and life-limiting autosomal recessive lysosomal storage disorder caused by variants in the NPC1 or NPC2 genes.⁴
尼曼-匹克病C型(NPC)是一种由NPC1或NPC2基因变异引起的超罕见、进行性且危及生命的常染色体隐性溶酶体贮积症。⁴
,
,
⁵ These variants impair the movement of cholesterol and other lipids within cells, leading to their accumulation in the brain and other organs.⁴
⁵这些变异会损害胆固醇和其他脂质在细胞内的转运,导致它们在脑部和其他器官中蓄积。⁴
,
,
⁵ NPC can cause a broad range of neurological and systemic symptoms that significantly impair daily functioning.⁵ Symptoms may begin at any age, from infancy through adulthood, and the disease's variable presentation can contribute to delayed diagnosis. NPC has an estimated incidence of approximately one case per 100,000 live births.⁵.
⁵ 尼曼-匹克病C型(NPC)可导致广泛的神经系统和全身症状,严重损害日常功能。⁵ 症状可能在任何年龄出现,从婴儿期到成年期不等,且该病临床表现多变,可能导致诊断延迟。据估计,NPC的发病率约为每10万例活产婴儿中有1例。⁵
About Ataxia-Telangiectasia
关于共济失调毛细血管扩张症
Ataxia-Telangiectasia (A-T) is a rare, inherited and progressive neurodegenerative disease caused by variants in the ATM gene that typically begins in early childhood.⁶ A-T is estimated to affect approximately one in 40,000 to 100,000 live births worldwide.⁶ The disease causes worsening problems with movement, coordination, speech and eye movements, and many people develop visible dilated blood vessels known as telangiectasias.⁶ A-T can also impair immune function and cause recurrent infections and serious pulmonary complications.
共济失调-毛细血管扩张症(A-T)是一种罕见的、遗传性的、进行性神经退行性疾病,由ATM基因变异引起,通常在幼儿期发病。⁶ 据估计,全球每40,000至100,000名活产婴儿中约有1人受A-T影响。⁶ 该病会导致运动、协调、言语和眼球运动方面的问题逐渐恶化,许多患者会出现可见的扩张血管,即毛细血管扩张。⁶ A-T还可能损害免疫功能,导致反复感染和严重的肺部并发症。
A-T is associated with a markedly increased risk of cancer, particularly leukemia and lymphoma, and significantly reduced life expectancy.⁶.
A-T 与癌症风险显著增加(尤其是白血病和淋巴瘤)以及预期寿命明显缩短相关。⁶
About Shionogi & Co., Ltd.
关于盐野义制药株式会社
Shionogi & Co., Ltd. is a 148-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of 'supplying the best possible medicine to protect the health and wellbeing of the patients we serve.' The company currently markets products in several therapeutic areas including anti-infectives, pain and CNS disorders.
盐野义制药株式会社是一家拥有148年历史的全球性、研发驱动型制药企业,总部位于日本大阪。公司秉持“提供最优质的药物,以保护所服务患者的健康与福祉”的企业理念,致力于为患者创造价值。目前,公司在包括抗感染、疼痛以及中枢神经系统疾病在内的多个治疗领域均有产品上市。
Shionogi's research and development currently targets infectious diseases and diseases with unmet medical needs, including rare diseases, allergy/inflammation, oncology, hearing loss, and sleep apnea. For more information on Shionogi & Co., Ltd., please visit .
盐野义的研发目前聚焦于传染病以及存在未满足医疗需求的疾病,包括罕见病、过敏/炎症、肿瘤学、听力损失和睡眠呼吸暂停。如需了解更多关于盐野义制药株式会社的信息,请访问。
https://www.shionogi.com/global/en
https://www.shionogi.com/global/en
.
。
About Shionogi Inc.
关于盐野义株式会社
Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a global research-driven pharmaceutical company. Today in North America, our FDA-approved infectious disease portfolio includes an antibiotic for serious infections caused by susceptible Gram-negative bacteria and an oral antiviral for post-exposure prophylaxis of COVID-19.
盐野义株式会社是一家全球研发驱动型制药企业,Shionogi Inc. 是其在美国的子公司。目前,在北美地区,我们获得美国食品药品监督管理局(FDA)批准的感染性疾病产品组合包括:一种用于治疗由易感革兰氏阴性菌引起的严重感染的抗生素,以及一种用于新冠病毒(COVID-19)暴露后预防的口服抗病毒药物。
Our FDA-approved rare disease portfolio includes therapies for amyotrophic lateral sclerosis (ALS), Niemann-Pick disease type C (NPC) and Ataxia in patients diagnosed with Ataxia-Telangiectasia (A-T). Our pipeline programs include investigational treatments across infectious disease, rare disease and additional high-need therapeutic areas.
我们获得美国食品药品监督管理局(FDA)批准的罕见病产品组合包括用于治疗肌萎缩侧索硬化症(ALS)、尼曼-匹克病C型(NPC)以及确诊为共济失调毛细血管扩张症(A-T)患者的共济失调的疗法。我们的研发管线项目涵盖针对传染病、罕见病以及其他高需求治疗领域的在研治疗方法。
Together with our subsidiaries Qpex Biopharma Inc. and Shionogi Canada Inc., we are continuing to innovate for patients in the U.S. and worldwide. Learn more at .
我们与旗下子公司Qpex Biopharma Inc.和Shionogi Canada Inc.携手,持续为美国及全球患者推进创新。了解更多,请访问。
shionogi.com
shionogi.com
.
。
About Shionogi B.V.
关于盐野义B.V.公司
Shionogi B.V. is the European subsidiary of Shionogi & Co., Ltd., a global, research-driven pharmaceutical company headquartered in Osaka, Japan. In Europe, Shionogi is dedicated to bringing benefits to patients by advancing innovative medicines in areas of significant unmet medical need. Our work focuses on infectious diseases and rare diseases, building on Shionogi's long-standing expertise in infectious diseases and growing commitment to addressing rare conditions.
Shionogi B.V. 是盐野义制药株式会社(Shionogi & Co., Ltd.)的欧洲子公司,后者是一家总部位于日本大阪、以研发为驱动的全球性制药公司。在欧洲,盐野义致力于通过在存在重大未满足医疗需求的领域推进创新药物,为患者带来福祉。我们的工作聚焦于传染病和罕见病,依托盐野义在传染病领域的长期专业积累,以及日益加强的对应对罕见疾病的承诺。
Shionogi also works with stakeholders across the healthcare ecosystem to support public health and strengthen health security in Europe. For more information about Shionogi in Europe, please visit .
盐野义还与医疗保健生态系统中的各利益相关方合作,以支持公共卫生并加强欧洲的健康安全。欲了解更多关于盐野义在欧洲的信息,请访问。
https://www.shionogi.com/eu/en/
https://www.shionogi.com/eu/en/
.
。
About Shionogi in Rare Disease
关于盐野义在罕见病领域的业务
Shionogi is committed to changing the trajectory of rare disease. Our mission is to transform the lives of people living with rare diseases by advancing breakthrough science into transformative medicines. We focus on areas where patients face profound unmet needs, bringing together scientific innovation, a focused development approach, and a deep commitment to patients, families and communities.
盐野义致力于改变罕见病的发展轨迹。我们的使命是通过将突破性科学进展转化为变革性药物,改善罕见病患者的生活。我们聚焦于患者面临巨大未满足需求的领域,融合科学创新、专注的研发方法以及对患者、家庭和社区的深切承诺。
Today Shionogi is delivering a meaningful therapy for patients living with amyotrophic lateral sclerosis (ALS) and, through ongoing research and development, is advancing the next generation of rare disease medicines..
如今,盐野义正在为肌萎缩侧索硬化症(ALS)患者提供具有临床意义的疗法,并通过持续的研发推动下一代罕见病药物的进步。
Forward-Looking Statements
前瞻性陈述
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate.
本公告包含前瞻性陈述。这些陈述基于在现有信息下作出的预期,并依赖于某些假设;这些假设受风险和不确定性的影响,可能导致实际结果与这些陈述存在重大差异。风险和不确定性包括总体国内和国际经济状况(如整体行业和市场状况),以及利率和汇率的变动。
These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations.
这些风险和不确定性尤其适用于与产品相关的前瞻性陈述。产品风险和不确定性包括但不限于:临床试验的完成和中止;获得监管批准;有关产品安全性和有效性的索赔和担忧;技术进步;重大诉讼的不利结果;国内和国外医疗改革以及法律法规的变化。
Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise..
对于现有产品,也存在制造和营销风险,包括但不限于无法建立满足需求的生产能力、原材料供应短缺以及竞争产品的进入。公司声明无意亦无义务因新信息、未来事件或其他原因而更新或修订任何前瞻性陈述。
For Further Information, Contact:
如需更多信息,请联系:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
盐野义网站咨询表单:https://www.shionogi.com/global/en/contact.html
U.S. Media: ShionogiCommunications@shionogi.com
美国媒体:ShionogiCommunications@shionogi.com
Shionogi Europe Press Office: pressoffice@shionogi.eu
盐野义欧洲新闻办公室:pressoffice@shionogi.eu
References
参考文献
1. AQNEURSA® (levacetylleucine) Full Prescribing Information. IntraBio Inc. Revised 9/2026. Accessed November 17, 2026.
1. AQNEURSA®(左乙酰亮氨酸)完整处方信息。IntraBio Inc. 修订于2026年9月。访问日期:2026年11月17日。
https://www.aqneursa.com/wp-content/prescribing-information.pdf
https://www.aqneursa.com/wp-content/prescribing-information.pdf
2. European Medicines Agency. Aqneursa, INN-levacetylleucine. Summary of Product Characteristics. Accessed November 17, 2026.
2. 欧洲药品管理局。Aqneursa,国际非专利名称-左乙酰亮氨酸。产品特性概要。访问于2026年11月17日。
https://www.ema.europa.eu/en/documents/product-information/aqneursa-epar-product-information_en.pdf
https://www.ema.europa.eu/en/documents/product-information/aqneursa-epar-product-information_en.pdf
3. U.S. Food and Drug Administration. FDA Approves Therapy to Treat Ataxia in Patients with Ataxia-Telangiectasia, a Rare Genetic Disorder. Accessed November 17, 2026.
3. 美国食品药品监督管理局。FDA批准用于治疗罕见遗传病毛细血管扩张性共济失调症患者共济失调的疗法。访问日期:2026年11月17日。
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-therapy-treat-ataxia-patients-ataxia-telangiectasia-rare-genetic-disorder
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-therapy-treat-ataxia-patients-ataxia-telangiectasia-rare-genetic-disorder
4. Wassif, C.A., et al. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genetics in Medicine. 2016; 18:41–48. Accessed November 17, 2026.
4. Wassif, C.A., 等. 通过分析大规模并行测序数据集预测未识别的内脏/神经系统晚发型尼曼-匹克病C1型的高发病率. 《遗传学医学》. 2016; 18:41–48. 访问日期:2026年11月17日.
https://www.sciencedirect.com/science/article/pii/S1098360021042921?via%3Dihub
https://www.sciencedirect.com/science/article/pii/S1098360021042921?via%3Dihub
5. Geberhiwot, T., et al. 2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C. Journal of Inherited Metabolic Disease. 2026; 49:e70185. Accessed November 17, 2026.
5. Geberhiwot, T., 等. 《尼曼-匹克病C型共识临床管理指南(2025)》. 《遗传代谢病杂志》. 2026; 49:e70185. 访问日期:2026年11月17日.
https://doi.org/10.1002/jimd.70185
https://doi.org/10.1002/jimd.70185
6. Rothblum-Oviatt C., et al. Ataxia telangiectasia: a review. Orphanet Journal of Rare Diseases. 2016; 11:159. Accessed November 17, 2026.
6. Rothblum-Oviatt C. 等。毛细血管扩张性共济失调:综述。《罕见病孤儿网期刊》。2016;11:159。访问于2026年11月17日。
https://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0543-7
https://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0543-7